Immunosuppressant Analogs in Neuroprotection

  • Cesario V. Borlongan
  • Ole Isacson
  • Paul R. Sanberg

Table of contents

  1. Front Matter
    Pages i-xxvii
  2. Immunosuppressants, Neurologic Disorders, and Neuroprotection

    1. Front Matter
      Pages 1-1
    2. Marcus F. Keep, Hiroyuki Uchino, Eskil Elmér
      Pages 3-32
  3. Immunosuppressants and Parkinson’s Disease

    1. Front Matter
      Pages 33-33
    2. Lauren C. Costantini, Ole Isacson
      Pages 49-66
    3. Joseph P. Steiner, Douglas T. Ross, Hansjorg Sauer, Theresa Morrow, Gregory S. Hamilton
      Pages 67-91
    4. Roger F. Castilho, Oskar Hansson, Patrik Brundin
      Pages 93-104
  4. Immunosuppressants and Other Age-Related Disorders

    1. Front Matter
      Pages 139-139
    2. Mark P. Mattson
      Pages 141-157
    3. Liza Leventhal, Jeffrey H. Kordower
      Pages 159-174
  5. Immunosuppressants, Stroke, and Traumatic Brain Injury

    1. Front Matter
      Pages 175-175
    2. A. L. McGregor, P. A. Jones, J. F. McCarter, T. E. Allsopp, J. Sharkey
      Pages 231-261
    3. David O. Okonkwo, John T. Povlishock
      Pages 263-281
  6. Immunosuppressants and Spinal Cord Injury

  7. Immunosuppressants and Sciatic Nerve Injury

    1. Front Matter
      Pages N3-N3
    2. Joseph P. Steiner, Heather Valentine, Theresa Morrow, Gregory Hamilton
      Pages 329-341
  8. Immunosuppressants and Other Disorders of the Central Nervous System

    1. Front Matter
      Pages N5-N5
    2. Shigeru Watanabe
      Pages 361-374
  9. Back Matter
    Pages 375-378

About this book


In recent years there has been a growing recognition that such widely used immunosuppressant drugs as cyclosporin and FK-506 and their analogs-the neuroimmunophilins-possess significant neurotrophic and neuroprotective properties in addition to their beneficial effects for transplant patients. In Immunosuppressant Analogs in Neuroprotection, pioneers in the field and leading neuroscientists and clinicians working with these drugs survey the most recent scientific evidence showing how they evolved from being purely immunosuppressant "drugs" to neuroprotective "agents." These authorities focus on recent preclinical evidence that demonstrates the neurotrophic/neuroprotective effects of immunosuppressants when administered alone or when combined with neural transplantation therapy in animal models of neurological disorders. They discuss their efficacy and mechanisms of action in vitro and in vivo; using these models of CNS disease, they report laboratory studies with compelling clinical indications for Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, spinal cord injury, ALS, sciatic nerve injury, and drug addiction. They also present novel hypotheses on the mechanisms of neuroprotection, ranging from the blockade of mitochondrial permeability transition pores to free radical scavenging to the inhibition of calcineurin.
Authoritative and cutting-edge, Immunosuppressant Analogs in Neuroprotection demonstrates that CsA, FK-506, and the immunophilins exert neuroprotective effects on their own and will serve well as a new breed of neuroprotective agents for the treatment of neurological disorders.


Alzheimer Nervous System Parkinson dopamine forebrain neurons transplantation

Editors and affiliations

  • Cesario V. Borlongan
    • 1
  • Ole Isacson
    • 2
  • Paul R. Sanberg
    • 3
  1. 1.National Institute on Drug AbuseBaltimoreUSA
  2. 2.Neuroregeneration LaboratoriesMcLean Hospital/Harvard Medical SchoolBelmontUSA
  3. 3.University of South Florida College of MedicineTampaUSA

Bibliographic information